+
Site Tour
SURGICAL AORTIC
VALVE SOLUTIONS
TISSUE HEART VALVES (THV)

 

Our latest aortic valve replacement solution for optimizing key clinical outcomes and the possibilities for patient lifetime management.

BUILT ON THE EPIC™PLATFORM THAT HAS STOOD THE TEST OF TIME

AT 10 YEARS

OVER 11.000 PATIENTS

94.6%*

Epic™ Supra Valve
Freedom From All-Cause
Reintervention2

OVER 1.900 PATIENTS

96.3%*

Epic™ Supra Valve
Freedom from SVD
(Structural Valve Degeneration)
All patient age3

COMMITED TO VALVE-IN-VALVE* FOLLOW-UP DATA


3-YEAR OUTCOMES OF VALVE-IN-VALVE INTERVENTION IN A U.S. POPULATION

>95.0%

Epic™ Supra Valve
Patients Experienced Freedom
from Valve Intervention4

OPTIMIZE OUTCOMES WITH EXCELLENT HEMODYNAMICS

ESTIMATED MEAN PRESSURE GRADIENT AT 1 YEAR FOR EPIC MAX (mm Hg)1

MEAN PRESSURE GRADIENT PREDICTED BASED ON MATCHED STENT ID FOR BIOCOR/EPIC™ VALVES.

Maximizing the internal orifice provides large effective orifice areas (EOAs) and low gradients to reduce the burden on the heart and contribute to better patient outcomes.


*The safety and effectiveness of valve-in-valve procedures in an Epic™ Max valve has not been established

BRINGING YOU...

Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions

 

TV

References
  1. [a] Biocor IFU [b] Maitland, Andrew, Gregory M. Hirsch, and Edward A. Pascoe. “Hemodynamic Performance of the St. Jude Medical Epic™ Supra Aortic Stented Valve.” Journal of Heart Valve disease 20.3 (2011): 327. [c] Epic Plus IFU
  2. Wiechmann, RJ., et. al. Ten-year Outcomes of Surgical Aortic Valve Replacement with a Contemporary Supra Annular Porcine Valve in a Medicare Population. JTCVS Open. 2022, doi.org/10.1016/j.xjon.2022.08.002.
  3. Lehmann S, Merk DR, Etz CD, Oberbach A, Uhlemann M, Emrich F et al. Porcine xenograft for aortic, mitral and double valve replacement: long-term results of 2544 consecutive patients. Eur J Cardiothorac Surg 2016;49:1150–6.
  4. H. Kenith Fang, et al. Three-Year Outcomes of Valve-in-Valve Intervention within the Epic™ Supra and Epic™ Mitral Valves in a Medicare Population. TVT Conference 2022; Chicago, USA; June 9th, 2022.

© Abbott 2024. All rights reserved. 9-EH-5-14981-01 02-2024

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline